NYSE:CTLT - Catalent Stock Price, News, & Analysis

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent Inc (NYSE:CTLT) announced its quarterly earnings data on Tuesday, February, 5th. The company reported $0.45 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.37 by $0.08. The company had revenue of $623 million for the quarter, compared to the consensus estimate of $608.38 million. Catalent had a return on equity of 17.42% and a net margin of 5.48%. Catalent's quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.45 EPS. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Catalent.

Catalent issued an update on its FY 2019 earnings guidance on Tuesday, February, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.5-2.59 billion, compared to the consensus revenue estimate of $2.51 billion.

8 brokerages have issued 1-year target prices for Catalent's stock. Their predictions range from $43.00 to $55.00. On average, they expect Catalent's stock price to reach $47.5714 in the next year. This suggests a possible upside of 9.2% from the stock's current price. View Analyst Price Targets for Catalent.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

Media stories about CTLT stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Catalent earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the company's share price in the next several days.

Some companies that are related to Catalent include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), Mylan (MYL), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ) and Loxo Oncology (LOXO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Energy Transfer LP Unit (ET), Abbott Laboratories (ABT), Cornerstone Total Return Fund (CRF), SunCoke Energy Partners (SXCP), Applied Materials (AMAT), Alibaba Group (BABA), Nucor (NUE), CBL & Associates Properties (CBL), Wells Fargo & Co (WFC) and Horizon Pharma (HZNP).

Catalent's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.85%), Brown Advisory Inc. (1.98%), D. E. Shaw & Co. Inc. (1.63%), GW&K Investment Management LLC (1.27%), Oregon Public Employees Retirement Fund (1.24%) and Macquarie Group Ltd. (1.22%). Company insiders that own Catalent stock include Barry Littlejohns, Christine Dolan, Donald E Morel, Jr, John J Greisch, John R Chiminski, Lance Miyamoto, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Macquarie Group Ltd., Westfield Capital Management Co. LP, Impax Asset Management Group plc, Bank of America Corp DE, Bank of New York Mellon Corp, SG Americas Securities LLC and Colony Group LLC. Company insiders that have sold Catalent company stock in the last year include Barry Littlejohns, John R Chiminski, Lance Miyamoto, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was bought by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Jennison Associates LLC, D. E. Shaw & Co. Inc., First Trust Advisors LP, Brown Advisory Inc., BlackRock Inc., Forsta AP Fonden and Geode Capital Management LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, John J Greisch and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $43.58.

Catalent has a market capitalization of $6.35 billion and generates $2.46 billion in revenue each year. The company earns $83.60 million in net income (profit) each year or $1.59 on an earnings per share basis. Catalent employs 10,700 workers across the globe.

The official website for Catalent is http://www.catalent.com.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]